BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Daniela Asslaber; Nathalie Wacht; Michael Leisch; Yuan Qi; Nicole Maeding; Clemens Hufnagl; Bettina Jansko; Nadja Zaborsky; Andreas Villunger; Tanja Hartmann; Richard Greil; Alexander Egle

doi:10.1158/1078-0432.CCR-18-1548

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Daniela Asslaber^* (Erstautor/-in), Nathalie Wacht (Co-Autor/-in), Michael Leisch (Co-Autor/-in), Yuan Qi, Nicole Maeding, Clemens Hufnagl (Co-Autor/-in), Bettina Jansko, Nadja Zaborsky (Co-Autor/-in), Andreas Villunger, Tanja Hartmann (Co-Autor/-in), Richard Greil (Co-Autor/-in), Alexander Egle (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Universitätsinstitut für experimentelle und klinische Zelltherapie
Universitätsinstitut für Pathologie
Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

36 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	190-1912
Fachzeitschrift	CLINICAL CANCER RESEARCH
Jahrgang	25
Ausgabenummer	6
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-1548
Publikationsstatus	Veröffentlicht - 2019

Zugriff auf Dokument

10.1158/1078-0432.CCR-18-1548

Dieses zitieren

Asslaber, D., Wacht, N., Leisch, M., Qi, Y., Maeding, N., Hufnagl, C., Jansko, B., Zaborsky, N., Villunger, A., Hartmann, T., Greil, R., & Egle, A. (2019). BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation. CLINICAL CANCER RESEARCH , 25(6), 190-1912. https://doi.org/10.1158/1078-0432.CCR-18-1548

Asslaber, Daniela ; Wacht, Nathalie ; Leisch, Michael et al. / BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation. in: CLINICAL CANCER RESEARCH 2019 ; Jahrgang 25, Nr. 6. S. 190-1912.

@article{90dbc536461548f29c9c324732bbd180,

title = "BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.",

keywords = "CHRONIC LYMPHOCYTIC-LEUKEMIA, TRANSGENIC MOUSE MODEL, FACTOR-RECEPTOR, CELL SURVIVAL, ACTIVATION, FAMILY, MUTATIONS, INDUCTION, BCL-2, BAFF",

author = "Daniela Asslaber and Nathalie Wacht and Michael Leisch and Yuan Qi and Nicole Maeding and Clemens Hufnagl and Bettina Jansko and Nadja Zaborsky and Andreas Villunger and Tanja Hartmann and Richard Greil and Alexander Egle",

note = "Asslaber, Wacht, Leisch, Qi, Maeding, Jansko, Zaborsky, Hartmann, Greil, Egle: Laboratory for Immunological and Molecular Cancer Research, Salzburg Cancer Research Institute, Salzburg Cancer Cluster, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Hufnagl: Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria",

year = "2019",

doi = "10.1158/1078-0432.CCR-18-1548",

language = "English",

volume = "25",

pages = "190--1912",

journal = "CLINICAL CANCER RESEARCH ",

issn = "1078-0432",

publisher = "Amer Assoc Cancer Research",

number = "6",

}

Asslaber, D, Wacht, N, Leisch, M, Qi, Y, Maeding, N , Hufnagl, C, Jansko, B, Zaborsky, N, Villunger, A, Hartmann, T, Greil, R & Egle, A 2019, 'BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.', CLINICAL CANCER RESEARCH , Jg. 25, Nr. 6, S. 190-1912. https://doi.org/10.1158/1078-0432.CCR-18-1548

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation. / Asslaber, Daniela (Erstautor/-in); Wacht, Nathalie (Co-Autor/-in); Leisch, Michael (Co-Autor/-in) et al.
in: CLINICAL CANCER RESEARCH , Jahrgang 25, Nr. 6, 2019, S. 190-1912.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

AU - Asslaber, Daniela

AU - Wacht, Nathalie

AU - Leisch, Michael

AU - Qi, Yuan

AU - Maeding, Nicole

AU - Hufnagl, Clemens

AU - Jansko, Bettina

AU - Zaborsky, Nadja

AU - Villunger, Andreas

AU - Hartmann, Tanja

AU - Greil, Richard

AU - Egle, Alexander

N1 - Asslaber, Wacht, Leisch, Qi, Maeding, Jansko, Zaborsky, Hartmann, Greil, Egle: Laboratory for Immunological and Molecular Cancer Research, Salzburg Cancer Research Institute, Salzburg Cancer Cluster, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Hufnagl: Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria

PY - 2019

Y1 - 2019

KW - CHRONIC LYMPHOCYTIC-LEUKEMIA

KW - TRANSGENIC MOUSE MODEL

KW - FACTOR-RECEPTOR

KW - CELL SURVIVAL

KW - ACTIVATION

KW - FAMILY

KW - MUTATIONS

KW - INDUCTION

KW - BCL-2

KW - BAFF

U2 - 10.1158/1078-0432.CCR-18-1548

DO - 10.1158/1078-0432.CCR-18-1548

M3 - Original Article

C2 - 30487125

SN - 1078-0432

VL - 25

SP - 190

EP - 1912

JO - CLINICAL CANCER RESEARCH

JF - CLINICAL CANCER RESEARCH

IS - 6

ER -

Asslaber D, Wacht N, Leisch M, Qi Y, Maeding N , Hufnagl C et al. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation. CLINICAL CANCER RESEARCH . 2019;25(6):190-1912. doi: 10.1158/1078-0432.CCR-18-1548